Even if the causality is not always established, a microbial imbalance or dysbiosis are being increasingly linked to several diseases, including gastrointestinal and dermal diseases, metabolic disorders, CNS pathologies and cancer. Furthermore, the microbiome has been shown to influence the efficacy of immunotherapy and chemotherapeutic agents and the metabolism of drugs. Based on preclinical and clinical studies, different strategies (e.g., fecal material, defined consortium, single strain) are adopted to modulate the composition of the microbiome and exploit its immunogenicity to treat diseases in first line treatment or to circumvent primary resistance to standard of care.
Owing to their scientific and technological expertise, Oncodesign and Taconic propose tailor-made strategies to clients for investigating the safety/efficacy of their microbiome-based therapeutics. This presentation will focus specifically on applications related to the use of pathogen-free and germ-free mice as preclinical models.
It will be a unique opportunity to interactively discuss, debate and have questions answered about how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.
Register for this webinar to gain deeper insight into preclinical models for evaluating microbiome products.
Sylvie Maubant, Head of Study & Research Unit - In Vivo Sciences Department, Oncodesign
Sylvie Maubant has more than 15 years of experience in preclinical research in the oncology field. She obtained a PhD in Biology, Medicine and Health from the University of Caen in France, and then she continued her career as a postdoctoral researcher at several institutes to work on projects related to identification of new therapeutic targets, drug development and/or validation of therapeutic tools in collaboration with industry partners. In 2014, Sylvie joined Oncodesign’s In Vivo Sciences Department as a study director. Since 2018, she has been mainly involved in bacteria-oriented programs for clients in different therapeutic areas. In 2021, she became the scientific referent for the company’s SOLO-microbiome offer.Message Presenter
Ivan Gladwyn-Ng, Field Application Scientist, Taconic
Ivan is a Field Application Scientist at Taconic Biosciences who is passionate about accelerating advancements in human health by improving the application of in vivo models and care of animals in the drug discovery process. He possesses more than a decade of experience in utilising rodent models within many diverse fields of preclinical research with particular interest in the studies of infectious, neurological, and oncological diseases. He has multiple co-first and corresponding authorships and successful patent applications in Europe and USA.
Prior to joining Taconic as a Field Application Scientist, he completed his postdoctoral training at GIGA Institute (Liege, Belgium), Institut Pasteur (Paris, France), Harry Perkins Medical Institute (Perth, Australia). He obtained his Ph.D. from the Australian Regenerative Medicine Institute (Melbourne, Australia) and completed his undergraduate studies (B.Sc., Med.) with First-Class Honours (top student) at Monash University (Melbourne, Australia).Message Presenter
Who Should Attend?
This webinar will be of interest to scientists from pharma companies, biotech companies, and academia, working on microbiome research in the areas of oncology, immuno-oncology and inflammatory diseases. Relevant job titles include, but are not limited to:
- Project Managers
- Study Directors
- Chief Scientific Officers
What You Will Learn
Join this webinar to learn about:
- The latest research in the study of the microbiome and its link to pathologies
- Models and services suitable for evaluating microbiome therapeutics
- Case studies focused on oncology and inflammatory diseases
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining artificial intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to select new therapeutic targets, as well as design and develop potential preclinical candidates through to clinical phases.
Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 230 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.
Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.